These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2164102)
1. Release by U-50,488H of [3H]serotonin from brain slices and spinal cord synaptosomes of U-50,488H-tolerant and nontolerant mice. Ho BY; Takemori AE J Pharmacol Exp Ther; 1990 Jul; 254(1):8-12. PubMed ID: 2164102 [TBL] [Abstract][Full Text] [Related]
2. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H. Ho BY; Takemori AE J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935 [TBL] [Abstract][Full Text] [Related]
3. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord. Bhargava HN; Gulati A; Ramarao P J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075 [TBL] [Abstract][Full Text] [Related]
4. beta-Endorphin-like immunoreactivity in discrete brain regions, spinal cord, pituitary gland and peripheral tissues of U-50,488H-tolerant and -abstinent rats. Bhargava HN; Matwyshyn GA; Rattan AK; Koo KL; Tejwani GA J Pharmacol Exp Ther; 1994 Feb; 268(2):856-61. PubMed ID: 8113998 [TBL] [Abstract][Full Text] [Related]
5. The antinociception produced by intrathecal morphine, calcium, A23187, U50,488H, [D-Ala2, N-Me-Phe4, Gly-ol]enkephalin and [D-Pen2, D-Pen5]enkephalin after intrathecal administration of calcitonin gene-related peptide in mice. Welch SP; Singha AK; Dewey WL J Pharmacol Exp Ther; 1989 Oct; 251(1):1-8. PubMed ID: 2552070 [TBL] [Abstract][Full Text] [Related]
6. Modification of the binding of [3H]MK-801 to brain regions and spinal cord of rats treated chronically with U-50,488H, a kappa-opioid receptor agonist. Bhargava HN; Kumar S Brain Res; 1997 Feb; 749(2):347-50. PubMed ID: 9138737 [TBL] [Abstract][Full Text] [Related]
7. Kappa opioid analgesia is dependent on serotonergic mechanisms. Vonvoigtlander PF; Lewis RA; Neff GL J Pharmacol Exp Ther; 1984 Nov; 231(2):270-4. PubMed ID: 6092612 [TBL] [Abstract][Full Text] [Related]
8. Effect of repeated administration of U-50,488H on the binding of 3H-SCH 23390 and 3H-spiperone to rat brain and spinal cord dopamine receptors. Bhargava HN; Ramarao P; Gulati A Prog Clin Biol Res; 1990; 328():153-6. PubMed ID: 2406759 [No Abstract] [Full Text] [Related]
9. Dynorphin prolongs the action potential of mouse sensory ganglion neurons by decreasing a potassium conductance whereas another specific kappa opioid does so by increasing a calcium conductance. Shen KF; Crain SM Neuropharmacology; 1990 Apr; 29(4):343-9. PubMed ID: 1971431 [TBL] [Abstract][Full Text] [Related]
10. Binding characteristics of [3H]SCH 23390 in spinal cord and discrete brain regions of kappa-opiate tolerant-dependent and abstinent rats. Bhargava HN; Gulati A; Ramarao P Pharmacology; 1991; 42(3):121-7. PubMed ID: 1647533 [TBL] [Abstract][Full Text] [Related]
11. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. Millan MJ; Członkowski A; Lipkowski A; Herz A J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723 [TBL] [Abstract][Full Text] [Related]
12. Involvement of serotonergic mechanisms in the inhibitory effect of U-50,488H on glutamate-induced lethality in mice. Kamei J; Igarashi H; Kasuya Y Res Commun Chem Pathol Pharmacol; 1992 Mar; 75(3):357-60. PubMed ID: 1509202 [TBL] [Abstract][Full Text] [Related]
14. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883 [TBL] [Abstract][Full Text] [Related]
15. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid. Vonvoigtlander PF; Lewis RA J Pharmacol Exp Ther; 1988 Jul; 246(1):259-62. PubMed ID: 2839665 [TBL] [Abstract][Full Text] [Related]
16. Dose-dependent antagonism and potentiation of nitrous oxide antinociception by naloxone in mice. Quock RM; Curtis BA; Reynolds BJ; Mueller JL J Pharmacol Exp Ther; 1993 Oct; 267(1):117-22. PubMed ID: 8229738 [TBL] [Abstract][Full Text] [Related]
17. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist. Bhargava HN; Ramarao P; Gulati A Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058 [TBL] [Abstract][Full Text] [Related]
18. Selective tolerance at mu and kappa opioid receptors modulating norepinephrine release in guinea pig cortex. Werling LL; McMahon PN; Cox BM J Pharmacol Exp Ther; 1988 Dec; 247(3):1103-6. PubMed ID: 2849659 [TBL] [Abstract][Full Text] [Related]
19. Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices. Suarez-Roca H; Maixner W J Pharmacol Exp Ther; 1993 Feb; 264(2):648-53. PubMed ID: 7679733 [TBL] [Abstract][Full Text] [Related]
20. Effect of chronic administration of U-50,488H, a kappa-opioid receptor agonist, on central dopamine D2 receptors of the rat. Veeranna ; Reddy PL; Bhargava HN Eur J Pharmacol; 1993 Apr; 235(1):23-30. PubMed ID: 8390939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]